Hologic (NASDAQ:HOLX) PT Lowered to $72.00

Hologic (NASDAQ:HOLX) had its price objective trimmed by Royal Bank of Canada from $74.00 to $72.00 in a research report released on Friday, Benzinga reports. The brokerage currently has a sector perform rating on the medical equipment provider’s stock.

Other analysts have also recently issued research reports about the stock. Bank of America lowered their target price on shares of Hologic from $94.00 to $86.00 and set a neutral rating on the stock in a research note on Tuesday, August 1st. StockNews.com initiated coverage on shares of Hologic in a research note on Thursday, October 5th. They issued a buy rating on the stock. Citigroup lowered their target price on shares of Hologic from $90.00 to $85.00 and set a neutral rating on the stock in a research note on Tuesday, August 1st. Raymond James lowered their target price on shares of Hologic from $95.00 to $85.00 and set an outperform rating on the stock in a research note on Wednesday, October 18th. Finally, TheStreet cut shares of Hologic from a b rating to a c+ rating in a research note on Monday, July 31st. Five investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of Moderate Buy and a consensus price target of $87.73.

Hologic Stock Up 7.3 %

Shares of HOLX opened at $72.13 on Friday. The company has a 50-day simple moving average of $69.61 and a 200-day simple moving average of $75.85. The firm has a market capitalization of $17.67 billion, a P/E ratio of 39.42 and a beta of 1.03. The company has a debt-to-equity ratio of 0.54, a quick ratio of 3.73 and a current ratio of 4.42. Hologic has a 52 week low of $64.02 and a 52 week high of $87.88.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Thursday, November 9th. The medical equipment provider reported $0.89 EPS for the quarter, beating analysts’ consensus estimates of $0.84 by $0.05. The business had revenue of $945.30 million during the quarter, compared to analyst estimates of $940.00 million. Hologic had a net margin of 11.31% and a return on equity of 18.96%. The firm’s revenue for the quarter was down .8% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.82 earnings per share. On average, equities research analysts expect that Hologic will post 3.92 earnings per share for the current year.

Institutional Investors Weigh In On Hologic

Several hedge funds have recently bought and sold shares of HOLX. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its holdings in Hologic by 5.1% in the first quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 33,448 shares of the medical equipment provider’s stock worth $2,569,000 after purchasing an additional 1,631 shares during the period. LSV Asset Management raised its holdings in Hologic by 307.5% in the first quarter. LSV Asset Management now owns 37,900 shares of the medical equipment provider’s stock worth $2,911,000 after purchasing an additional 28,600 shares during the period. Raymond James Trust N.A. raised its holdings in Hologic by 7.4% in the first quarter. Raymond James Trust N.A. now owns 6,875 shares of the medical equipment provider’s stock worth $528,000 after purchasing an additional 476 shares during the period. Dimensional Fund Advisors LP raised its holdings in Hologic by 4.8% in the first quarter. Dimensional Fund Advisors LP now owns 2,305,399 shares of the medical equipment provider’s stock worth $177,098,000 after purchasing an additional 106,315 shares during the period. Finally, Aviva PLC increased its position in shares of Hologic by 0.7% during the first quarter. Aviva PLC now owns 75,543 shares of the medical equipment provider’s stock worth $5,803,000 after acquiring an additional 513 shares in the last quarter. 92.64% of the stock is currently owned by institutional investors and hedge funds.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health.